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Abstract: Ricin toxin (RT) is derived from castor beans, produced by the plant Ricinus 
communis. RT and its toxic A chain (RTA) have been used therapeutically to arm ligands 
that target disease-causing cells. In most cases these ligands are cell-binding monoclonal 
antibodies  (MAbs).  These  ligand-toxin  conjugates  or  immunotoxins  (ITs)  have  shown 
success in clinical trials [1]. Ricin is also of concern in biodefense and has been classified 
by the CDC as a Class B biothreat. Virtually all reports of RT poisoning have been due to 
ingestion of castor beans, since they grow abundantly throughout the world and are readily 
available. RT is easily purified and stable, and is not difficult to weaponize. RT must be 
considered during any ―white powder‖ incident and there have been documented cases of 
its  use  in  espionage  [2,3].  The  clinical  syndrome  resulting  from  ricin  intoxication  is 
dependent upon the route of exposure. Countermeasures to prevent ricin poisoning are 
being developed and their use will depend upon whether military or civilian populations 
are at risk of exposure. In this review we will discuss ricin toxin, its cellular mode of 
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action,  the  clinical  syndromes  that  occur  following  exposure  and  the  development  of  
pre- and post-exposure approaches to prevent of intoxication. 
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1. Ricin Toxin 
RT  is  a  disulfide-linked  heterodimeric  glycoprotein  consisting  of  the  toxic  RTA  and  the  
cell-binding B chain (RTB). RTA is an N-glycosidase that specifically cleaves the 28S ribosomal RNA 
at  adenine  4324.  RTB  is  a  galactose-specific  lectin,  that  binds  to  cell-surface  glycolipids  and 
glycoproteins found on all vertebrate cells. The toxin is extracted from castor beans, where it consists 
of 3–5% of the bean‘s dry weight [2]. Ricinus communis grows worldwide in warm temperate and 
tropical climates. It is cultivated as an ornamental plant and used commercially for its oil; it also grows 
as  a  weed.  Castor  oil  is  extracted  for  its  utility  as  a  high  temperature  lubricant.  Following  the 
extraction  of  the  oil,  the  toxin  can  be  purified  from  the  remaining  mash  by  sodium  hydroxide 
precipitation  (crude preparation) or by  chromatography. However,  even crude RT is  highly toxic; 
pulverized beans are a potential bioweapon. The purified toxin is a white powder, and is quite stable at 
temperatures below 60° . However, even when boiled, high does of RT can be lethal (Vitetta et al., 
unpublished). The ubiquity of castor beans, ease of extraction, and chemical stability, make ricin an 
attractive and inexpensive agent for scientifically unsophisticated individuals or nations to produce in 
large quantities. The LD50 of ricin toxin varies according to the route of exposure, 5–15 µg/kg by 
aerosol or parenteral administration, 25–100 mg/kg orally [2,4,5] or 5–15 µg/kg by gastric gavage 
following a period of fasting [6]. While RT is 100-fold less toxic than botulinum toxin, even smaller 
scale events in civilian populations could lead to panic and economic disruption, which are the basic 
objectives of terrorism [7]. Given the history of RT-related events [2,3,7], there is no question that it 
will at some point be used in an act of terrorism. Indeed caches of RT have been found throughout  
the  world  [7]  and  in  August,  2011  it  was  reported  by  the  New  York  Times  that  Al-Qaeda  was 
experimenting with ricin bombs. 
2. Cellular Toxicity of RT 
RT is a biochemically simple molecule, which must be routed to specific sites in the cell to exert its 
toxicity [8]. As a result, the processing of RT has been well studied and informative regarding unique 
trafficking pathways in the cell, notably ―reverse transport‖. There are several excellent review articles 
that describe the intracellular processing of RT [2,9–13]. This review will focus on those aspects of RT 
that can be targeted by antibodies or other inhibitors and the reader is referred to the cited reviews for 
biochemical details. 
RTB  binds  to  cells  via  its  lectin  receptors  [9].  Because  many  cell  surface  glycoproteins  and 
glycolipids display terminal galactosyl residues, RT binds promiscuously to virtually all cell types. 
Because each RT monomer can bind to two galactose-containing residues, RT can also cross-link 
some cell surface molecules. The binding of the toxin to cells is a target for intervention, by both 
antibodies and competitive ligands [14]. We routinely use 0.1 M lactose or galactose solutions to block Toxins 2011, 3                        
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the cellular cytotoxicity of RT in vitro. Milk contains a similar concentration of lactose, and thus we 
use the milk-based Blocker 
TM BLOTTO to block non-specific binding of glycoproteins to ricin in 
immunoassays. One wonders whether the antidote to ricin ingestion might not be a simple glass of 
milk,  assuming  it  is  given  within  a  short  period  of  time.  To  our  knowledge  this  has  not  been 
investigated. It is also possible that microbial polysaccharides bind to RT at mucosal sites, and thus 
hinder its binding to human cells. This could account for the low toxicity of orally administered RT. 
RT is internalized from the cell surface via a variety of mechanisms, both clathrin dependent and 
independent, and dynamin dependent and independent. By cross-linking cell surface molecules, and 
signaling through cell surface kinases, it is possible that RT can upregulate its own uptake into cells [9]. 
Because RT can bind to a number of cell surface glycan-containing structures, as well as glycoproteins 
in  the  serum  and  tissues,  it  is  likely  to  be  internalized  by  the  full  gamut  of  uptake  mechanisms, 
including phagocytosis and micropinocytosis. Since the mechanisms of intake of RT differ in different 
cells as well as within the same cell, it can be deposited in different intracellular sites.  
Much of the initial intracellular routing of RT involves shuttling among endosomal compartments. 
Ricin may follow three paths from the endosomes. The first involves exocytosis and expulsion from 
the cell, likely involving blebbing. Figure 1 shows micrographs of this process. The blebbing might 
indicate an attempt by the cell to expel the toxin. It might also represent a potential way for active ricin 
to be transferred to other cells in a tissue. The second pathway leads to lysosomal degradation. It is 
only by the third, retrograde, route that RT reaches its intracellular site of action. RT traverses the 
same set of organelles involved in the secretion of proteins, but does so in the reverse direction used by 
secreted proteins, moving from the endosomes, through the Golgi, and into the ER. Initially it was 
believed that this retrograde path was unique to toxins, but it has been found to be a regular feature of 
intracellular trafficking [9,10,13]. Drugs that specifically inhibit this pathway have been developed and 
have  been  show  to  be  effective  anti-RT  agents,  both  in  cells  and  in  animals,  albeit  at  very  high 
concentrations [8]. 
Once RT reaches the endoplasmic reticulum, it must be translocated across the ER membrane into 
the cytosol, where it exerts its toxicity. Within the ER, the holotoxin is reduced, and RTA is released. 
The  RTA  then  unfolds,  crosses  the  ER  membrane  and  translocates  into  the  cytosol  [15,16].  To 
successfully accomplish this, the unfolded A chain must avoid ubiquitination and the ER-associated 
degradation pathway, while still utilizing protein conducting translocons that are part of the degradation 
pathways. This is accomplished through the use of chaperones including Hsc70 and Hsp90 [16], as 
well as by a temperature-dependent structural alteration in RTA, involving the loss of alpha-helical 
structures and insertion of the C-terminus into the membrane lipid bilayer of the ER [15].  
Once at its site of action, RTA acts as an N-glycosidase, depurinating ribosomal RNA by removing 
adenine 4324 in the RTA/sarcin loop of the 28S rRNA. The enzyme inactivates 1500 ribosomes per 
minute. The high catalytic rate has been found to be due, in part, to movement of the RNA structure 
itself [17]. It has been proposed that a helical domain of RTA, (amino acids 99–106) also plays a key 
role  in  depurination,  and  that  the  function  of  this  domain  might  be  hindered  by  an  antibody  
(Ab)-mediated attack [18]. Chemical analogues that mimic RNA‘s transition states during catalytic 
cleavage have been studied as potential inhibitors of RT [19–22].  
It has been estimated that for each functional RT molecule that reaches its site of action, 10,000 
other internalized molecules have either been degraded, eliminated by exocytosis, or sequestered in Toxins 2011, 3                        
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functionally irrelevant compartments in the cell  [23]. Cell death results from inhibition of protein 
synthesis and is primarily by apoptosis. 
Figure 1. Expulsion of ricin from intoxicated cells. Cells were labeled with a nuclear dye 
(blue), and with Bodipy-brefeldin A, which labels ER and Golgi (red). Ricin (green) was 
added  at  3  min  post  initiation  of  timing,  shown  as  min:sec  in  the  time  series.  Within  
15  min  the  ricin  has  begun  to  colocalize  with  the  Bodipy-BFA  (showing  orange). 
Individual ricin-coated blebs move outward from the cell, most clearly seen between the 
latter time points. 
 
3. Beneficial Uses of Ricin 
The authors of this review first studied RT because of its therapeutic potential, primarily as the 
toxic  moiety  of  MAb-based  immunotoxins  (ITs).  ITs  are  part  of  a  larger  class  of  agents,  termed 
immunoconjugates (ICs), that consist of a targeting moiety linked to a cytotoxic moiety. If the toxic 
moiety  is  a  protein  toxin  or  its  active  subunit,  these  ICs  are  called  ITs.  Projects  under  active 
investigation  in  our  laboratories  include  ITs  to  treat  lymphomas  and  leukemias  [24–26],  ITs  as 
immunomodulatory  agents  [27],  and  ITs  to  eliminate  the  latent  reservoir  of  HIV  that  remains 
following  antiretroviral  treatment  [28,29].  The clinical  efficacy  of  ITs  and  immunoconjugates  has 
clearly been demonstrated in human clinical trials [30]. While there was initial concern regarding the 
widespread inherent toxicity of ITs, this was not the case; the major-dose limiting toxicity in early 
trials was vascular leak syndrome (VLS).  
When compared to cytotoxic agents used to treat cancer, RT is far more potent. Figure 2 shows 
agents that target CD4+ lymphoma cells. RT is 4 logs more potent (on a molar basis) than the most 
active  cytotoxic  drugs.  Although  RT  has  a  relatively  high  molecular  weight,  MAbs  armed  with  Toxins 2011, 3                        
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1–2  molecules  of  RT  retain  antigen  binding.  For  the  smaller  cytotoxic  agents,  that  number  is 
approximately 10 molecules bound to each MAb. Thus even by conjugating more cytotoxic drug per 
molecule of MAb, it is unlikely that a cytotoxic drug-conjugate will achieve the toxicity of the most 
potent RT/RTA-based ITs. We have coupled the same anti-HIV MAb to RTA and to doxyrubicin, and 
found excellent in vitro and in vivo killing with the RTA IT, but only non-specific killing with the 
doxyrubicin conjugate (C. Coyne and SHP, unpublished).  
Figure 2. Comparative toxicity of ricin and chemotherapeutic agents on lymphoma cells. 
The comparative cytotoxic effect of chemotherapeutic agents and ricin was studied in the 
C8166  CD4+  lymphoma  line  using  MTS  dye  reduction.  On  a  molar  basis,  ricin  was  
4 logs more toxic than the smaller drugs. 
 
Given the high degree of toxicity, as well as its general reputation as an agent of bioterrorism, it is 
no surprise that there have been concerns about the therapeutic use of RT. Considerable effort has gone 
into reducing the non-specific toxic side-effects of RTA-based ITs. VLS, hepatotoxicy, and nephrotoxicty 
were  the  major  dose-limiting  effects  of  very  early  ITs.  It  was  subsequently  found  that  mannose 
residues on the plant-derived RTA led to binding of RTA to mannose receptors on liver cells [31–34] 
and  thus  chemically  or  enzymatically  deglycosylated  RTA  (dgRTA)  was  subsequently  used.  The 
molecular  basis  of  VLS  has  been  studied  [35,36],  and  it  may  be  reduced  with  anti-inflammatory  
drugs [37] or by altering the three amino acids in RTA that bind to endothelial cells and cause VLS. [36]. 
RTA is a proinflammatory and immunogenic molecule. RT and RTA can in rare cases be allergens. 
The presence of antibodies against RTA leads to rapid clearance of RTA-ITs from the blood, such that 
its  efficacy  is  reduced.  Hence,  instead  of  a  half-life  of  several  days,  it  can  be  cleared  in  hours. 
However, if one waits 2–8 weeks, titers of antibody drop to baseline and further doses can be given. 
Several  approaches  have  been  taken  to  specifically  suppress  the  development  of  anti-IT  immune 
responses,  including  the  concomitant  administration  of  immunosuppressive  agents  such  as 
cyclosporine, deoxyspergualin, anti-CD4 antibodies, or CTLA-4-IgG [38–44], or the development of 
tolerance with agents such as polyethylene glycol [45–47]. 
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4. Ricin as a Weapon of Bioterrorism 
RT is of concern in the area of biodefense because it is readily available to individuals or groups 
with little technical expertise or funding. Its source is a ubiquitous weed and a cultivated crop in many 
countries. Crude RT made from pulverized castor beans is toxic and a 2-step extraction with readily 
available  chemicals  yields  >95%  pure  toxin.  The  toxin  is  chemically  stable  and  can  be  stored 
unrefrigerated  for  long  periods  of  time  with  little  loss  of  activity.  Over  the  past  several  decades,  
there  have  been  well-documented  instances  of  RT  prepared  for  nefarious  uses,  and  at  least  one  
well-documented assassination with RT [2,3,7]. Although some have underplayed the risk from RT, 
primarily because it is unlikely to cause mass casualties [7], we should not underestimate the panic and 
disruption that can result from a biological attack initiated by a lone lunatic, even if it only involves a 
small number of individuals. Public assurances that an antidote is at hand will greatly allay anxiety and 
act as a deterrent. 
Measures designed to protect people from the lethal effects of RT will be different for civilian and 
military populations. For civilians, any one individual is at very low risk of exposure, but there is a 
high likelihood that there will eventually be an attack against the public that will likely involve a 
limited number of individuals. In this case, post-exposure treatment is most appropriate. In addition to 
developing appropriate therapies, effective use of post-exposure strategies will require recognition of 
the event by alert first responders, rapid confirmation of an attack via specific assays, obtaining the 
appropriate therapeutic agents, and administering them, all within a limited window of time (<24 h). 
Since the symptoms of RT poisoning do not appear for hours, and they are difficult to distinguish from 
many other common infections, this will be challenging. A factor that strongly mitigates the risk of 
exposure by a large population is the difficulty in delivering RT in uniformly lethal quantities. As 
discussed below, aerosol exposure is most likely to produce serious symptoms. Delivery of either 
dissolved toxin or milled powder requires particle size less than 3 microns [48], larger particles rapidly 
settle  and  cannot  penetrate  the  pulmonary  system  as  deeply.  Particles  <  1  micron  may  remain 
suspended  as  aerosols  indefinitely.  Hence  some  technical  expertise  would  be  needed  to  produce 
optimally weaponized aerosols, although this could be done by trained individuals working for an 
enemy group. As noted earlier, however, larger quantities of crude ricin could be effectively used  
as well.  
For the military, entire personnel units are likely to be exposed as a group. However, in this setting, 
RT has limited utility. The amount required for aerosol toxicity is large (10 µg/kg), compared to 
botulinum toxin (100 ng/kg), for example. Dispersion over a battlefield or military encampment is 
highly dependent upon weather conditions and technical expertise. Nevertheless, if the military were 
facing an enemy thought to have ricin in its arsenal, then pre-exposure preventative measures, which 
might include physical barriers, chemical detoxification agents, and immunization [6,49–52], should 
be planned. 
5. Routes of Exposure 
The route by which one is exposed to RT is a key determinant of the clinical symptoms observed. 
Military groups are most likely to be exposed via the aerosol route, whereas attacks against civilians 
could be by aerosol, ingestion, or possibly even injection. RT could be used in solution or in its Toxins 2011, 3                        
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powdered form. Even if aerosolized particles are not small enough to be fully inhaled into pulmonary 
spaces, damage to mucosal tissues is still possible. There are a number of unresolved issues regarding 
the  clinical  syndromes  associated  with  RT  exposure,  among  them:  Does  the  oral  route  pose  a 
significant risk to humans? Clearly the ingestion of castor beans can be fatal, but this might be due to 
the protective effect of the seed coat in the upper GI. It is not clear what the effect of pure toxin either 
in suspension or as a powder will be in humans. Several excellent reviews of the clinical effects of 
ricin have been written [2–5,7]. However, it should be emphasized that there are almost no human data 
regarding  exposure  to  the  pure  toxin,  so  that  the  signs  and  symptoms  attributed  to  RT  exposure 
syndrome have, for the most part, been extrapolated from animal data. 
5.1. Oral Exposure 
The effects of ricin given orally vary depending upon whether purified toxin or castor beans are 
ingested, whether the toxin is administered by gavage feeding or orally, whether there is a full or 
empty stomach, and other factors. More than 1000 cases of human ingestion of castor beans have been 
reported. Release of toxin from the beans requires digestion and delipidation of the bean matrix, and 
thus the toxin is not released until it reaches the lower small intestine or the large bowel. Chewing the 
beans more thoroughly may increase toxin release. Symptoms attributable to the ingestion of castor 
beans occur primarily in the lower GI tract where RT can induce cramping, diarrhea, and blood in the 
stool. These can result in fluid and electrolyte imbalances. Even more serious sequelae, resulting from 
damage to the intestinal tissue, can occur. Mortality from castor bean ingestion may approach 2% [7].  
All  published  studies  of  oral  toxicity  of  RT  have  been  performed  in  small  animals,  primarily 
rodents, and have utilized direct instillation of the toxin into the stomach (gavage feeding). Although 
gavage feeding allows for rapid and accurate dosing, it bypasses the oral mucosa and the esophagus, 
two sites where pathology and clinical findings may originate. Lethal doses for gavage feeding have 
generally been in the 15–35 mg/kg range, that is 1000×  higher than the dose reported for aerosol or 
injection routes [53–56], although in mice fasted for 20 hours prior to gavage feeding, the lethal dose 
may be lowered 100 to 1000-fold [6]. At doses of 35 mg/kg, administered orally to mice, there was no 
clinical  effect,  no  mortality,  and  only  marginal  pathological  findings.  (K.  Song,  S.H.  Pincus, 
unpublished). Mortality was observed at 100 mg/kg. However, this involved feeding a mouse the 
human equivalent of 2 L of ricin at 25 mg/mL over 3 hours, and could have resulted in some degree of 
aspiration of ricin into the airways, where the lethal dose is 10,000-fold less. Withholding food before 
feeding ricin did not increase susceptibility. Thus it may be possible that purified RT, as compared to 
castor beans, has limited, if any, toxicity by the oral route. 
It is not clear why purified RT administered by mouth is less toxic than when introduced by gavage 
directly into the stomach. It implies a degree of resistance of the oral and esophageal tissues to the 
toxic effects of RT. One possibility is that the microbial flora express carbohydrate structures with 
terminal  galactose  residues,  and  the  microbial  saccharides  compete  with  host  glycoproteins  and 
glycolipids on tissue surfaces. Alternatively, a host saccharide in the saliva or other oral/esophageal 
secretions may be competing with tissues for ricin binding [96].  
In any case, laboratory rodents may not be adequate as surrogates for studying oral exposure of 
humans, since their oral and esophageal mucosa differ markedly from those of humans. Because their 
herbivore diet largely consists of hard, fibrous material (mouse chow), the oral and esophageal mucosa Toxins 2011, 3                        
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of rodents maintains a luminal surface with a highly cornified layer of stratified epithelium, whereas in 
humans it is only minimally keratinized, and may be more easily damaged by direct action of the 
toxin. Entirely aside from the question of susceptibility of the upper GI tract to ricin-mediated damage, 
is the matter of taste. Castor oil, extracted from the castor bean and used as a purgative for many years, 
is  notable  for  its  terrible  taste.  The  CDC  states  that  ricin  is  odorless  and  tasteless 
(http://www.bt.cdc.gov/agent/ricin/clinicians/background.asp) but if the toxin is insufficiently pure and 
retains even a small portion of the taste of the castor oil, it may prove impossible to feed the requisite 
amount of toxin to cause toxicity. To address both of these issues, it is critically important to determine 
the oral  toxicity of ricin  in  a non-human primate, whose esophageal  mucosa is  similar to that  of 
humans and where taste aversion can be studied. If ricin is not palatable or non-toxic in these animals, 
then we can lower our level of concern regarding risks of oral exposure in human populations.  
5.2. Inhalation Exposure 
Aerosolized RT is widely considered to be the most lethal route of exposure and certainly the one 
that has the potential to injure or kill the greatest number of victims in a terrorist attack. However, 
generating a fine aerosol that remains airborne at a sufficiently high concentration is technically more 
difficult than adding it to food or water. Most of the studies examining the toxicity of aerosolized RT 
have  been  performed  in  rodents  but  results  are  consistent  with  the  limited  data  available  from  
non-human primates [2,5]. In mice, aerosolized RT has an LD50 of 3–5 μg/kg. When it is inhaled, the 
size of the aerosol particle correlates  inversely  with  the severity of lung damage,  i.e.  the smaller 
particles can penetrate more deeply into the lungs and cause more damage [2]. Most of the damage is 
observed within the lungs, which indicates that little toxin escapes from the mucosa. The resulting 
necrosis and inflammation lead to non-cardiogenic pulmonary edema and infiltration of immune cells. 
Subjects usually die of respiratory failure. Despite the localization of toxin in the lungs, systemic 
inflammation  is  still  observed  and  can  lead  to  arthralgias  and  fever.  Understandably,  it  has  been 
observed  that  pulmonary  exposure  to  RT  upregulates  genes  involved  in  inflammation  and  tissue 
remodeling, as well as the release of various cytokines and chemokines [56–59]. 
5.3. Injection of RT 
RT injected intraperitoneally (i.p.), intramuscularly (i.m.), or subcutaneously (s.c.) has LD50s of 5 to 
24 μg/kg. While this is nearly as lethal as inhaled aerosolized ricin, injections are not suitable for use 
as a ―weapon‖ although RT has been used this way in the setting of espionage. The best documented 
case of this involved the 1978 assassination of Georgi Markov, a Bulgarian journalist and defector; a 
toxin-laden pellet was fired into his leg from the tip of an umbrella as he waited for a London bus. He 
died a few days later in hospital, since there was not (and still is not) a specific antidote for RT 
poisoning.  
As for the other routes, there are limited data in humans but they also compare well with animal 
data. Following injection, tissue necrosis is observed at the injection site (Markov reported immediate 
local pain). Within a few hours there is systemic inflammation, fever and hypotension, resulting in ‗flu 
like  symptoms‘  that  mimic  many  other  diseases.  Systemically,  injection  results  in  severe  local 
lymphoid necrosis, gastrointestinal hemorrhage, liver necrosis, diffuse nephritis, and diffuse splenitis. Toxins 2011, 3                        
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Alterations in liver transaminases, amylase, creatinine kinase, bilirubin, and myoglobin have also been 
reported following exposure. In mice, systemic injection of RT results in lethal hypoglycemia, with little 
evidence of other metabolic abnormality [60]. RT exerts its toxicity on many different cell types and 
so it may not be possible to pinpoint the exact cause of death.  
6. Protective Measures 
Different populations at risk require distinct approaches to protection. For military units facing an 
enemy that is believed to have RT in its arsenal, immunization is the most logical approach. For 
civilians, where the likelihood of any one individual being exposed to the toxin is low, the emphasis 
needs to be placed on post-exposure treatment. Civilians will not accept the use of a vaccine unless 
there  are  continuing  attacks.  Unfortunately,  post-treatment  therapy  requires  early  recognition  of 
intoxication, rapid confirmation of the exposure, and easy access to specific treatment. This is difficult 
since the early symptoms can mimic those of many diseases including influenza.  
In this section we will discuss approaches to the prevention and treatment of RT toxicosis. Both 
specific and non-specific measures will be discussed. The authors of this article believe that antibodies 
currently offer the greatest potential for the development of specific RT inhibitors. Perhaps this is no 
surprise, since we are immunologists. This section will close with a discourse on passive and active 
antibody therapies. Active immunization will be of interest to the military and perhaps civilian first 
responders, whereas passive therapies are optimal for post-exposure treatment in any population. 
6.1. Public Health Approaches to Containing Risk 
Measures that assess and mitigate risks in populations can be applied to the matter of poisoning by 
RT  or  other  toxins  [2,3,7].  These  measures  would  include  an  accurate  depiction  of  the  expected 
clinical syndrome. Of the likely routes of exposure, both the oral and parenteral routes lack a clear 
definition. Next, this information needs to be disseminated to those healthcare workers who are likely 
to encounter victims of an attack, so that they will consider RT poisoning in differential diagnosis. We 
also need appropriate diagnostic tools that allow the rapid and specific identification of intoxication by 
RT. This includes not only assays for detection as a white powder, but also assays that are validated for 
use in human body fluids. Immunoassays are most likely to be used for this purpose.  
Beyond  this,  population  approaches  diverge  depending  whether  military  forces  or  civilians  are 
being  considered.  Critical  to  protecting  the  military  is  good  intelligence.  Foreknowledge  of  the 
presence of large stores of RT by one‘s enemy would allow deployment of physical barriers, chemical 
decontamination  procedures,  stockpiling  of  useful  therapeutic  agents,  and  consideration  of  active 
immunization. We do not have access to military assessments and planning for such exposures. 
Procedures  for  the  protection  of  civilians  have  been  the  subject  of  discussion,  resulting  in  the 
publication of guidelines for the response to a RT incident [3]. But key gaps do exist. Informatic tools 
to link doctor‘s offices, hospital emergency rooms, and free standing ―instant care‖ facilities to identify 
outbreaks  in  dispersed  patients  need  to  be  developed  [61].  Assays  providing  confirmation  of  the 
toxin‘s presence in clinical samples have yet to be approved. Perhaps most worrisome of all, is that the 
critical steps and processes for recognition of an ―RT incident‖ and steps to mitigate the effects are left 
to our overworked and underfunded state and local health departments, emergency rooms, and primary Toxins 2011, 3                        
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care facilities. It seems ironic that even as the government funds the development of new epidemiologic 
tools, diagnostics and treatments, we allow the crumbling of our primary bulwark against bioterrorism, 
the public health infrastructure. 
6.2. Post-Exposure Therapies 
Post-exposure treatments fall into two general categories, specific anti-RT agents and non-specific 
supportive therapies [2–5]. At the present time only the latter exist. RT-specific antibodies will be 
discussed in a separate section. Supportive therapies would include eliminating residual ricin from the 
body by exhaustive washing of affected mucosal or dermal tissues, and by gastrointestinal lavage. 
Maintaining proper fluid and electrolyte balance is critical. Following aerosol exposure, third-spacing 
of  large  volumes  of  fluid  in  the  lungs  occurs  through  the  induction  of  inflammatory  exudates,  
injury-caused  transudation,  and  frank  hemorrhage  [48,62].  Similarly,  diarrhea  and  hemorrhage 
associated with  castor bean ingestion has  been  reported to  cause substantial  fluid  loss. Following 
aerosol  exposure,  respiratory  support  may  be  necessary.  This  may  include  supplemental  oxygen, 
continuous positive airway pressure breathing, and artificial ventilation. The use of pressor drugs to 
mitigate circulatory collapse may be required in advanced cases. Corticosteroids and therapies directed 
at inhibiting inflammatory cytokines may blunt the inflammation that creates much of the pathology, 
especially that seen following aerosol exposure [56–59]. 
If they existed, small molecule inhibitors of ricin toxicity might be used to treat patients who have 
been  exposed  to  ricin.  They  may  also  be  used  prophylactically,  if  it  were  deemed  likely  that  an 
exposure would occur. As yet, there are no specific ricin antidotes that have been approved for use, 
although several therapeutic targets are being explored in drug-discovery laboratories. These include 
agents that block the binding of RTB to cell-surface glycans [14], agents that block N-glycosidase 
activity  [19–22,63],  or  specifically  inhibit  retrograde  transport  through  the  protein  synthetic  
pathway [8]. Of these, only the inhibitors of retrograde transport have been tested in animals, and 
found to be somewhat effective in ameliorating ricin‘s toxicity at acceptable doses. In vitro efficacy of 
the  others  is  in  the  micromolar  range,  with  varying  degrees  of  non-specific  cytotoxicity,  and  are 
unlikely to result in a therapeutic effect in vivo. 
6.3. Active and Passive Immunization 
As indicated earlier, the authors  are proponents  of immune therapies for RT toxicosis.  Both  a 
vaccine for active immunization [6,49–52] and antibodies for passive immunization [64–66] are under 
development. A vaccine is a pre-exposure preventive measure that is most likely to be utilized by the 
military, whereas  passively  administered  antibodies can be used either as  post-exposure treatment 
(civilians or military) or as prophylaxis for a very high-risk and short-term exposure (military). 
6.3.1. Passive Administration of Antibodies 
Passive  immunization  predates  the  development  of  antibiotic  therapies,  circa  WWII.  Antibody 
therapy has seen a resurgence in recent years with the development of MAb technologies, protein 
engineering,  and  much  improved  biochemical  techniques  for  the  purification  and  formulation  of 
immunoglobulin (Ig) preparations [67–69]. One of the few universally agreed upon truths of the field Toxins 2011, 3                        
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of vaccinology is that antibodies are the primary mode of protection from toxins. Vaccines that protect 
against bacterially-derived tetanus and diphtheria elicit protective antibodies against the toxin, and do 
not  affect  the  organism  directly.  Passive  antibody  therapies  to  treat  bacterial  infections  in  which 
pathology is mediated by toxins, such as anthrax and pseudomembraneous colitis, have undergone 
clinical testing [70,71]. Thus there is great interest in how antibodies function to neutralize toxins. The 
general belief is that antibodies neutralize toxins by blocking their binding to target cells. Yet for many 
toxins, including RT, anti-RTA antibodies can be as effective as  anti-RTB antibodies. This raises 
questions as to the mechanism by which anti-RTA antibodies neutralize RT. This could occur by 
preventing binding, internalization, or routing of the RTA to the endosomal compartment after the 
formation  of  immune  complexes.  Recent  studies  using  quantitative  confocal  microscopy  and  cell 
kinetic experiments, clearly demonstrate that anti-RTA neutralizes by altering intracellular trafficking 
and by neutralizing the toxin inside the cell (S. Pincus and K. Song, submitted for publication). These 
studies also demonstrate that antibody can protect cells even when added 8 hours after the cells have 
been exposed to RT. 
The key question in defining the utility of passive antibody therapies is whether the antibody can 
have a protective effect in people when administered after a 12–24 hour delay, the minimum amount 
of time to recognize and confirm a RT exposure, and then to obtain and administer the antibody. 
Animal studies show in vivo protection by MAb RAC18 occurs even when administration is delayed 
by 12 hours [64,65]. Among other issues to be resolved are: which antibody to use; whether to target 
RTA,  RTB  or  both;  the  use  of  polyclonal  vs  monoclonal  antibody,  intact  antibody  or  antibody 
fragments; and whether systemic or local administration is better. Figure 3 provides data concerning 
some of these issues. 
A number of groups have evaluated different anti-RT MAbs for protection in vitro, in vivo, or  
both [18,66,72–79]. Unfortunately, most antibodies have not been compared side-by side. In our own 
studies with a panel of 38 different murine anti-RTA or RTB MAbs or to compound epitopes on both 
chains, we have found antibody affinity to be the most important determinant of in vitro protection 
([66] and S. Pincus and K. Song, submitted). Epitope specificity may also play a role [66,78,79]. For  
in vivo protection, antibody isotype and Fc-mediated effects may also be important [80]. We, and 
others, have found that anti-RTA antibodies are generally more protective than anti-B chain antibodies 
in vitro (Figure 4, and reference [66], although others have reported the opposite [76]). 
Figure 3 compares the efficacy of a polyclonal Fab preparation to that of our best anti-RTA and 
RTB  MAbs,  RAC18  and  RBC11,  respectively.  The  polyclonal  antibodies  were  elicited  by 
immunization of horses with an RTA/RTB chain construct, in which the native inter-chain linking 
domain has  been replaced by an uncleavable linker. The animals  were hyperimmunized and then 
repeatedly bled. IgG was purified from the plasma, and a mixture of Fab and F(ab)‘2 fragments were 
prepared by proteolytic digestion (Figure 3A). Most of the mixture consisted of F(ab)‘2. Because the 
Fc, a site of many species-specific epitopes, has been removed, these Abs are termed ―despeciated‖ 
with the expectation of reduced immunogenicity. Concentration of RT- binding antibody was 32 µg 
per mg of total protein, as determined by Biacore analysis under conditions of partial mass transport 
limitation [81]. RT binding by the equine Fab preparation was markedly less than that of RAC18 and 
RBC11 as determined by ELISA (Figure 3B), even when recognizing that only 3.2% of the polyclonal 
preparation  is  RT-specific  Fab.  The  reverse  occurred  when  antibody-mediated  neutralization  was Toxins 2011, 3                        
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determined (Figure 3C). The equine Fab was 30X more potent than the best MAb, RAC18. Equimolar 
concentrations of horse Fab (6.6 µg/mL) and intact RAC18 have inhibition curves that completely 
overlap, yet only a small fraction (3.2%) of the polyclonal preparation is RT-specific. Figure 3C also 
demonstrates that a Fab fragment derived from RAC18 has marginally lower neutralization activity 
than the intact antibody. Figure 3D shows greater neutralization by anti-RTA than by anti-RTB MAb. 
It also shows that additive effects can be obtained when the two are mixed. Together these results 
demonstrate that Fab fragments can neutralize toxin in vitro, and that there may be advantages to 
polyclonal preparations. 
Figure 3. In vitro neutralization of ricin by polyclonal horse Fab preparations and MAbs. 
Panel A. Agilent microcapillary electrophoresis of intact monoclonal RTAs, MAb against 
RTA (RAC18 IgG vs. RAC18 Fab), and the polyclonal horse anti-ricin ―Fab‖ preparation, 
under  reducing  and  non-reducing  conditions.  The  horse  antibody  preparation  consists 
primarily of F(ab)‘2 fragments. Panel B. ELISA binding of antibodies to plates coated with 
RT. Different secondary enzyme-conjugated antibodies were used to detect the horse and 
mouse  Igs.  Antibody  concentration  represents  total  protein.  For  MAbs,  100%  is  
RT-specific  antibody,  whereas  for  the  horse  Fab,  only  3.2%  is  RT  specific.  Panel  C.  
In vitro neutralization of RT cytotoxicity by intact antibody and Fab fragments. Antibody 
concentration represents total protein. No antibody and control antibodies yield identical 
curves. Panel D. In vitro neutralization by high titer antibodies against RTA, (RAC), RTB 
(RBC), or both. Antibodies were used at 10 µg/mL. 
 
The development and utilization pathway for anti-RT antibodies is fairly straightforward. A central 
agency must ultimately choose one optimal antibody formulation. Ultimately, this will be determined 
by demonstrating protection in a non-human primate aerosol challenge model. The best efficacy would 
be determined after a delay of 12–24 hours following exposure to  the toxin. Formulations  of the 
antibody would be stockpiled at locations that are sufficiently dispersed to accomplish delivery to any Toxins 2011, 3                        
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exposed individual. Point of care diagnostic tests and standards must also be established. Health care 
workers  must  know  how  to  order  antibodies  from  central  stockpiles  capable  of  providing  service 
within hours. Of course, the majority of these steps also apply to many other infectious health threats.  
Figure 4. Crystal structure representations of the recombinant RTA vaccines. RTA active 
site residue side chains shown in red, VLS residue side chains (L74, D75 and V76) in blue, 
and dominant immunogenic epitopes in green. A. Wild type RTA; B. RTA1–33/44–198 
(USAMRIID)  vaccine:  portions  of  the  structure  genetically  excised  shown  in  orange;  
C. Ricin-MPP (Warwick) vaccine: point of 25-mer insertion shown in orange (with arrow); 
D. RiVax (Texas) vaccine: Y80A V76M residue side chains shown in orange (Y80A has 
an arrow). (PDB accession No. 1RTC for panels A, B, and C, 3BJG for panel D. 
 
6.3.2. Active Immunization  
As discussed above, active vaccination is probably not suitable for the public at large, but would be 
useful  for  military  personnel,  who  might  be  intentionally  targeted,  as  well  as  emergency  first 
responders,  who  are  the  most  likely  to  be  exposed  domestically,  either  accidentally  during  an 
investigation of an individual in possession of small amounts, or during a terrorist attack. Only if RT 
were  used  repeatedly  in  domestic  terrorist  attacks  would  the  public  be  vaccinated.  As  such,  the 
availability  of  effective  countermeasures,  including  post-exposure  therapies  and  a  stockpile  of  an 
active vaccine, might serve as a deterrent. The ideal vaccine would protect against ricin exposures by 
any route, but in particular a mucosal route, since this would be the most likely route of exposure. For 
A
. 
B
. 
C
. 
D
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large emergency immunization campaigns, the vaccine should have a long shelf life and induce the 
formation of long-lived protective antibodies after 1 or 2 doses. 
Several approaches to actively vaccinate against RT have been investigated. The most straightforward 
approach to generating a vaccine against any toxin is to irreversibly convert it into an inactive toxoid 
using  heat  or  chemicals.  However  this  process  must  preserve  the  key  epitopes  necessary  for 
immunization. Ricin toxoid has been extensively studied in rodent models, both as subcutaneous (s.c.) 
injections and as various microsphere formulations administered mucosally [82–85]. It was effective in 
preventing death but did not prevent lung damage following aerosol or intratracheal exposures. Toxoid 
administered orally, alone or as a microsphere formulation, showed only minimal protection against 
inhaled RT. However, the toxoid has or can regain residual toxicity and has been considered too risky 
for a vaccine.  
An alternative to ricin toxoid is to vaccinate with one of its two subunits, RTA or RTB, which are 
orders of magnitude less toxic than the holotoxin. Deglycosolated (dg) RTA has been evaluated for use 
as a vaccine. Deglycosylation prevents liver uptake and therefore liver damage [86,87]. Most of the 
studies using dgRTA were concerned with generating a good mucosal response, apparently in the 
belief  that  this  was  absolutely  required  for  protection  against  a  mucosal  challenge.  However,  as 
discussed  below,  we  and  others  have  developed  recombinant  RTA  vaccines  that,  when  given 
systemically, protect mice against aerosolized and orally administered ricin. Hence there is no absolute 
requirement  for  local  sIgA  production.  Various  dgRTA  formulations  with  or  without  mucosal 
adjuvants  were  tested  in  rodents  but  none  induced  titers  comparable  to,  or  protected  as  well  as, 
mucosally administered toxoid [88,89]. This lack of success, combined with concerns that it is too 
toxic for human use, even though it approximately three logs less toxic than RT, has resulted in it 
being dropped from consideration. Instead three different laboratories have chosen the safer approach 
of developing recombinant RTA vaccines. As shown in Figure 4, each utilizes a different strategy to 
eliminate  the  cytotoxic  activity  while  maintaining  immunogenic  epitopes  critical  for  inducing 
protective neutralizing antibodies [49,90,91]. 
As noted previously [49,90,91], one recombinant RTA consisted of the RTA subunit containing  
a 25 amino acid fragment to disrupt the enzymatic active site (Figure 4B). The rationale for this was 
based  upon  a  precursor  state  of  homologous  proteins  found  in  plants.  In  these  plants  a  Type  III 
ribosome inactivating protein (RIP) is produced as a zymogen that has an amino acid insert which 
interferes with the active site until it is converted to the active state by post-translational excision of 
this  fragment.  Rats  vaccinated  with  this  construct  were  protected  against  ricin  delivered  via  the 
intratracheal route. While immunogenic and protective in animals, residual catalytic activity made it an 
unlikely candidate for a human vaccine [90]. It is not known at this time whether this vaccine is 
undergoing further development.  
Another strategy was to genetically eliminate the entire hydrophobic face of RTA that is normally 
shielded by RTB in  the holotoxin,  in  an effort  to  increase solubility and stability. This  truncated 
molecule, RTA 1-33/44-198 (Figure 4C), was more stable and less prone to aggregation during long 
term storage. This deletion also removed a portion of the active site and so this molecule also lacks 
enzymatic  activity.  This  truncated  subunit  vaccine  still  retains  known  important  immunogenic 
peptides, however the large deleted portion may contain other unidentified but important protective 
epitopes. This vaccine did not induce VLS activity in vitro [92] and performed very well in mice Toxins 2011, 3                        
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challenged  with  either  injected  or  aerosolized  ricin.  However,  lung  function  following  aerosol 
challenge  was  not  reported.  The  vaccine  was  effective  in  non-human  primates  (Leonard  Smith, 
personal  communication)  and  has  been  shown  to  be  immunogenic  and  non-toxic  in  rabbits  in  a  
pre-clinical toxicology study [93]. 
In  view  of  our  discovery  that  dgRTA-containing  ITs  induce  VLS  via  a  (x)D(y)  motif  in  
RTA [35,36], we chose to engineer RTA to modify both the N-glycosidase and the VLS sites. Two 
point mutations, one in each of the two sites (Figure 4D), were introduced into the structural gene to 
generate  a  non-toxic  highly  immunogenic  vaccine  to  protect  mice  against  ricin  [49].  The  crystal 
structure of this construct, Y80A V76M (RiVax) was nearly identical to the wild type RTA, suggesting 
that the majority of the conformational epitopes should be intact [94]. RiVax has proven to be highly 
soluble and stable in a variety of formulations. Administered i.m., it is protective in mice in each of the 
three challenge models we have tested, oral gavage, injected or inhaled aerosol [6]. In the aerosol 
model, lung function tests and histological examinations at intervals post-exposure demonstrated that 
RiVax protected the mouse lungs in a dose dependent manner. This is important since the vaccine 
must also protect against debilitating damage, even if it is reversible, which appears to be the case. 
Since it is generally believed that i.m. vaccination does not induce mucosal secretory immunoglobulin 
A(sIgA) responses, we hypothesize that high titers of serum IgG antibody are sufficient to protect mice 
from a mucosal challenge with RT. This was confirmed by Neal, et al. [95], who immunized mice 
lacking secretory IgA using RiVax/alum administered s.c. and found that they were protected against 
RT administered by gavage, further substantiating our findings and our hypothesis. As compared to 
administration of RiVax administered i.m. when RiVax was given via the intradermal (i.d.) route we 
found a marginal improvement in its ability to induce protective antibody titers [52]. This vaccination 
route would be ideal for situations where rapid immunization of large groups was required. We have 
also completed one clinical trial of the vaccine (without adjuvant) in humans and have found the 
vaccine to be safe and immunogenic [51]. A second trial using an alum formulation is ongoing. This 
vaccine has been out-licensed to Soligenix for more advanced clinical trials and (hopefully) eventual 
FDA approval as an orphan drug for military personnel. 
7. Future Considerations 
Since several passive and active vaccines appear promising, it is important that the best of these 
reach the national stockpile for future use. Because RT is considered by many not to be a high priority 
biothreat  the funding needed to  accomplish  this  is  difficult  to obtain. Considering the efforts and 
resources  already  spent  developing  RT  vaccines  and  antibodies,  and  the  relative  certainty  that  an 
incident will occur in the future, we view this as short-sighted and hope that government officials will 
rethink this policy. 
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